Tagged with

Switzerland Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to market in the past four years, the road still to travel to ensure better outcomes for chronic disease patients in Switzerland, and the leadership he hopes to cultivate during the COVID-19 pandemic…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…

France A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics biotech Novacyt’s remarkable rise, and a new job for former Ipsen boss Marc de Garidel.   Sanofi aims for COVID-19…

Switzerland While Switzerland has Europe’s second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and in management positions. However, this situation is changing and two of Switzerland’s most important pharma affiliates are at the forefront of a new wave of diverse Swiss leadership teams.…

USA Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing access and driving down costs in the process.   2020 has been an exceptionally turbulent year – especially for the…

USA Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in culture, and the company’s multifaceted response to the COVID-19 crisis.   In general, through the global COVID response, we’ve seen the walls between companies and across sectors come down as…

Switzerland Pfizer Switzerland’s Sabine Bruckner discusses Switzerland’s historic and continuing importance to Pfizer, vaccine development and uptake, and the significant benefits of building a diverse leadership team.   There are challenges and opportunities in every situation and, while there is no doubt that COVID-19 is challenging for all of us, it…

USA Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech success story like Amicus can be a guiding light in market access and pricing discussions. Ultimately, we envision our competition…

Switzerland Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in Switzerland, why internal innovation remains the company’s core focus, and how stakeholder relations have had to evolve in the COVID-19 era.   One advantage of being a family-owned rather than a…

China Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company. The company’s CEO spoke to PharmaBoardroom about how Edigene’s technology platforms differ from those of other firms, and why the…

Brazil Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known internationally but play a leading role in what is the world’s sixth largest pharma market, serving a patient population of…

Roundup The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.   Six Indian drug…